Co-Diagnostics and CoSara Advance Ebola PCR Test Development and Co-Dx™ PCR Point-of-Care Platform Capabilities
Rhea-AI Summary
Co-Diagnostics (Nasdaq: CODX) and joint venture CoSara reported progress in developing Ebola PCR tests and expanding the Co-Dx™ PCR point-of-care platform.
The program includes a pan-Ebola assay to detect multiple ebolavirus species and a multiplex assay to differentiate Sudan, Taï Forest, Zaire, and Bundibugyo strains, with planned point-of-care, blood-based testing on Co-Dx PCR Pro®, all subject to further development and regulatory review.
Positive
- Dual-assay Ebola PCR program targeting detection and differentiation of multiple ebolavirus species
- Planned first blood-based pathogen assay for the Co-Dx PCR Pro® platform
- Expansion of Co-Dx PCR platform beyond swab-based infectious disease testing
- Strategy supports point-of-care deployment in outbreak and surveillance settings
- International infrastructure via CoSara enables localized manufacturing and deployment
Negative
- Ebola assays remain under development and require validation before use
- All Co-Dx PCR platform components are subject to FDA and other regulatory review
- Co-Dx PCR platform and associated tests are not yet available for sale
News Market Reaction – CODX
On the day this news was published, CODX gained 0.32%, reflecting a mild positive market reaction. Argus tracked a peak move of +50.4% during that session. Argus tracked a trough of -19.3% from its starting point during tracking. Our momentum scanner triggered 21 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $104K to the company's valuation, bringing the market cap to $32.72M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 26 | Ebola strategy update | Positive | +79.7% | Advanced PCR strategy with CoSara for Bundibugyo and pan-Ebola detection. |
| May 19 | Private placement | Negative | +28.4% | $3.0M at-the-market private placement with common and pre-funded warrants. |
| May 19 | Ebola assay strategy | Positive | +43.8% | Completion of Bundibugyo virus assay strategy on Co-Dx PCR platform. |
| May 14 | Q1 2026 earnings | Negative | -21.2% | Low revenue, high operating expenses and net loss, plus cash update. |
| May 8 | JV facility lease | Positive | +31.1% | CoMira JV finalized lease for Sudair PCR manufacturing facility. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
CODX has often seen strong upside on positive partnership and Ebola assay updates, while earnings pressure led to a notable selloff. A prior private placement saw a positive price reaction, diverging from typically negative financing sentiment.
Over the past month, CODX issued several notable updates. On May 8, its CoMira JV secured a ~14,400 sq ft Saudi manufacturing site, with shares up 31.09%. Q1 2026 results on May 14 showed revenue of $0.15M and a net loss of $9.1M, followed by a -21.17% move. Subsequent Ebola assay strategy news on May 19 and May 26 drove gains of 43.8% and 79.68%, highlighting strong market sensitivity to outbreak-related platform updates, which this new Ebola PCR progress further extends.
Key Terms
pan-ebola assay medical
multiplex assay medical
point-of-care medical
pcr medical
blood-based pathogen assay medical
regulatory review regulatory
ngos other
fda regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Dual-assay strategy designed to support outbreak response and surveillance efforts in affected regions
Potential blood-based Ebola assay would represent an important expansion of Co-Dx™ PCR point-of-care platform capabilities
This dual-assay strategy is intended to provide flexibility in supporting outbreak response efforts, including those of potential NGO partners, subject to future development, validation, regulatory review, and deployment requirements.
"Our ability to rapidly develop and deploy molecular diagnostic solutions for emerging infectious disease threats is one of the most important differentiators of the Co-Dx platform," said Dwight Egan, Chief Executive Officer of Co-Diagnostics. "The progress we are making with Ebola reflects not only the flexibility of our assay design capabilities, but also the value of the international infrastructure we have built through CoSara. As outbreaks emerge around the world, combining rapid assay development with localized manufacturing and deployment capabilities positions us to respond quickly when new diagnostic needs arise."
The Ebola PCR assay workflow configurations also being developed to support point-of-care environments for the Co-Dx PCR point-of-care platform* would represent the first blood-based pathogen assay designed for use on the Co-Dx PCR Pro®. This would significantly expand the platform's capabilities beyond swab-based infectious disease testing and increase the range of potential applications that may be addressed through future menu expansion.
Mr. Egan continued, "Many of the world's most serious infectious diseases are identified using blood samples, and expanding the platform to support those applications would represent an important step forward for Co-Diagnostics. The ability to bring rapid, high-quality PCR testing closer to patients, whether through respiratory, tuberculosis, HPV, or blood-borne disease applications, supports our broader goal of making molecular diagnostics more accessible in both developed and emerging markets."
*The Co-Dx PCR platform (including the PCR Home®, PCR Pro®, mobile app, and all associated tests) is subject to review by the FDA and/or other regulatory bodies and is not yet available for sale.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently for sale) and to identify genetic markers for use in applications other than infectious disease.
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will," "seeks," "anticipates," and similar expressions, or the negative of these terms. Forward-looking statements in this press release include, but are not limited to, statements regarding: (i) the Company's ability to execute its assay joint development strategy for Ebolavirus tests with CoSara Diagnostics; (ii) the potential future development, validation, regulatory review, commercialization, manufacture, and distribution of the tests; (iii) the Company's ability to rapidly respond to emerging infectious disease threats; (iv) the potential utility, effectiveness, and adoption of the Co-Dx PCR platform for decentralized diagnostics and outbreak monitoring, including for blood-borne pathogens; and (v) potential collaborations with governmental and non-governmental organizations relating to infectious disease preparedness and response. Such statements are subject to a number of risks and uncertainties, including, without limitation: risks that market demand or public health conditions may change; risks related to the Company's ability to successfully develop, validate, obtain regulatory authorization or approval for, manufacture, and commercialize any Ebola assay or related products; risks related to regulatory review by the FDA or other regulatory authorities; risks related to the performance, reliability, and market acceptance of the Co-Dx PCR platform; risks associated with dependence on third parties, suppliers, collaborators, and distribution partners; risks related to competition, technological change, and intellectual property protection; and other risks described from time to time in the Company's filings with the Securities and Exchange Commission ("SEC"). Actual results may differ materially from those expressed or implied in these forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements. A further description of risks and uncertainties can be found in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2026, and in its other filings with the SEC. The Company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release, except as required by applicable law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-and-cosara-advance-ebola-pcr-test-development-and-co-dx-pcr-point-of-care-platform-capabilities-302788234.html
SOURCE Co-Diagnostics